Abstract
Background: There has been a constant pursuit for development of newer therapies which can contribute to the relatively nascent field of cardioprotection in the setting of myocardial ischemiareperfusion injury. One novel cardioprotective agent among others, that has shown promising results in the limited number of research studies undertaken till now, is Urocortin. Urocortins are peptides belonging to the Corticotropin-Releasing Hormone family.
Results: Acting through a variety of downstream mechanisms, urocortin has been shown to alter cellular metabolism and modulate the mechanism of cell death occurring as a result of ischemia-reperfusion injury. New evidence continues to accumulate in support of urocortin’s beneficial role in cytoprotection.
Conclusion: We present here an updated review largely focused on the various mechanisms through which urocortin alters cellular metabolism, and discuss the clinical potential of urocortin’s cardioprotective ability in myocardial ischemia-reperfusion injury.
Keywords: Urocortin, ischemia-reperfusion, cytoprotection, corticotropins, cell death, cellular metabolism, myocardial.
Graphical Abstract
Current Molecular Pharmacology
Title:Cardioprotective Utility of Urocortin in Myocardial Ischemia- Reperfusion Injury: Where do We Stand?
Volume: 11
Author(s): Craig Basman, Pratik Agrawal, Richard Knight, Louis Saravolatz, Chad McRee, Carol Chen-Scarabelli, Jagat Narula and Tiziano Scarabelli*
Affiliation:
- Virginia Commonwealth University Medical Center Department of Cardiology, Alabama,United States
Keywords: Urocortin, ischemia-reperfusion, cytoprotection, corticotropins, cell death, cellular metabolism, myocardial.
Abstract: Background: There has been a constant pursuit for development of newer therapies which can contribute to the relatively nascent field of cardioprotection in the setting of myocardial ischemiareperfusion injury. One novel cardioprotective agent among others, that has shown promising results in the limited number of research studies undertaken till now, is Urocortin. Urocortins are peptides belonging to the Corticotropin-Releasing Hormone family.
Results: Acting through a variety of downstream mechanisms, urocortin has been shown to alter cellular metabolism and modulate the mechanism of cell death occurring as a result of ischemia-reperfusion injury. New evidence continues to accumulate in support of urocortin’s beneficial role in cytoprotection.
Conclusion: We present here an updated review largely focused on the various mechanisms through which urocortin alters cellular metabolism, and discuss the clinical potential of urocortin’s cardioprotective ability in myocardial ischemia-reperfusion injury.
Export Options
About this article
Cite this article as:
Basman Craig, Agrawal Pratik, Knight Richard, Saravolatz Louis, McRee Chad, Chen-Scarabelli Carol, Narula Jagat and Scarabelli Tiziano*, Cardioprotective Utility of Urocortin in Myocardial Ischemia- Reperfusion Injury: Where do We Stand?, Current Molecular Pharmacology 2018; 11 (1) . https://dx.doi.org/10.2174/1874467210666170223101422
DOI https://dx.doi.org/10.2174/1874467210666170223101422 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases
Recent Patents on Cardiovascular Drug Discovery Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Biological Responses to Hydrogen Molecule and its Preventive Effects on Inflammatory Diseases
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Bradykinin is Involved in the Mediation of Cardiac Nociception during Ischemia through Upper Thoracic Spinal Neurons
Current Neurovascular Research IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design